Notícias

Shares in the company fell more than 4% as its CEO laid out plans for new blockbuster drugs in the next few years.

Novo Nordisk shares plunged in early trading as the company pledged to launch more than five blockbuster drugs and deliver more than $23 billion in new sales in coming years. The plans disappointed investors hoping for more concrete turnaround plans from Chief Executive Officer Mike Doustdar after the Danish drugmaker lost its lead in the booming obesity market to Eli Lilly. Bloomberg's Sanne Wass reports.

Eli Lilly’s updated fair value estimate has shifted from US$1,297.31 to US$1,325.39, adding a fresh data point to an already closely watched price target range. This move sits alongside analyst price targets that often sit above US$900, with a cluster between US$1,300 and US$1,600, as research teams debate how much of the GLP-1 and obesity story is already reflected in the stock. As you read on, you will see how to track these evolving views and what they may mean for your own Eli Lilly...

The US Department of Health and Human Services will get a portion of the increased revenue if Pfizer Inc. is able to charge higher drug prices abroad, according to newly released documents.

Investing.com -- Artificial intelligence is moving beyond text generation into scientific research, creating investment opportunities across AI infrastructure, pharmaceuticals, nuclear fusion, industrial materials and utilities, according to UBS Wealth Management.

The consumer health company’s GLP-1 shelf strategy at CVS is paying off, and bigger retailers could follow.

It's plugging into a state-of-the-art research tool developed by a major pharmaceutical company.

Readers weigh in on energy investments, retirees’ dilemma, a Social Security fix, lessons from 9/11, and the case for natural-gas company Equinor.

Eli Lilly (LLY) trades near $1,150, up about 52% over the past year, and is now worth more than a trillion dollars. At that size the easy read is that the big money has been made. But Lilly has barely started selling Foundayo, its oral obesity medicine, outside the United States. So how much is left? The scenario below starts from Lilly's own trailing numbers, but the growth, margin, and multiple it assumes are ours. It is not a forecast and not a price target.

Eli Lilly stakes its trillion-dollar valuation on mid-stage data for a two-drug obesity combo, and the September 30 readout will reveal whether eloraTZP is a genuine franchise leap or an expensive gamble on incremental gains.

Johnson & Johnson (JNJ) stock has returned about 57% over the past year, against about 17% for the S&P 500. On the earnings it has already banked, that price looks expensive. But those earnings carry STELARA, which is losing share to biosimilar competition. What looks dear on earnings already reported comes down sharply on the earnings analysts expect.

Healthcare stocks declined late Friday afternoon, with the NYSE Healthcare Index and the State Stree

Merck (MRK) stock returned about 87% over the past twelve months, climbing from roughly $79 to about $147. Nothing in the year's results looks like that. The medicines Merck sells today grew at their usual pace. Investors spent the year repricing what comes next.

Novo Nordisk A/S (NYSE:NVO) decision to use “Novo” as its day-to-day name is part of a broader attempt by CEO Mike Doustdar to reset the company’s culture and sharpen its competitive focus. The rebrand comes as Novo tries to regain momentum in obesity drugs after losing ground to Eli Lilly. Doustdar’s new “Novo Way” emphasizes […]

Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.

These companies may perform well in any market environment.

AZN's pipeline setbacks weigh on its stock, but a deep late-stage pipeline and 20+ expected readouts offer key catalysts.

JNJ's growth gets a boost from new drug launches and pipeline wins, but Stelara's patent loss and MedTech headwinds remain key risks.

Eli Lilly & Co. has surged about 300% since its first GLP-1 was approved over four years ago, propelling it past $1 trillion in market value and making it the world’s most valuable pharmaceutical company.

Eli Lilly (NYSE:LLY) has entered an exclusive research collaboration with QurCan Therapeutics to develop genetic medicines for nervous system diseases. The agreement centers on QurCan's polymer lipid nanoparticle delivery platform for central and peripheral nervous system targets, with Eli Lilly responsible for later development and commercialization. Lilly is also making a strategic investment in QurCan Therapeutics, tying capital directly to progress in genetic medicine delivery...

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Doctors are exploring whether weight-loss drugs could also treat conditions such as endometriosis and Crohn’s disease.

On September 8, 2026, CNBC reported that Novartis’ failed pelacarsen trial has raised the stakes for rival experimental cholesterol drugs from Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY), both of which are racing to prove that lowering lipoprotein(a), or Lp(a). It can meaningfully reduce heart attacks and strokes. Analysts said Amgen’s olpasiran faces […]

Twist traded as high as $163.70 on Thursday and finished the session about 9% higher near $156.

Eli Lilly (LLY) grew revenue 48% in Q2 2026, driven by Zepbound and Mounjaro. A more understated metric for investors to watch is pricing. Lilly's U.S. price fell 9% from a year earlier, excluding changes to rebate estimates. So far, volume covers that cut. The risk is the quarter it cannot.

On September 15, Berenberg upgraded its rating on Eli Lilly and Company (NYSE:LLY) from Hold to Buy and lifted its price target from $1,220 to $1,400. The research firm pointed to the company’s strong returns on investment and its growth in the obesity treatment market. Berenberg said its 2026 return on research investment analysis confirms […]

On August 31, 2026, Reuters reported on a new study finding that patients who stay on the lowest starter doses of GLP-1 weight-loss drugs still lose weight, though far less than at full recommended doses, and experience less nausea. Patients on Eli Lilly and Company (NYSE:LLY)’s low-dose tirzepatide lost an average of 5.5% of their […]

LLY's GLP-1 momentum, Foundayo launch and retatrutide pipeline support growth, but premium valuation and rising competition weigh on the stock.

NVO's 5% drop in a week reflects intensifying GLP-1 competition and semaglutide risks, but its broad pipeline offers potential long-term growth.

Danish drugmaker Novo Nordisk (NVO) and Orbis Medicines struck an up to $1.4 billion licensing deal